AI assistant
Guerbet — Earnings Release 2011
Oct 25, 2011
1392_iss_2011-10-25_a6391952-9fb0-45c9-b7cd-ae5732566a30.pdf
Earnings Release
Open in viewerOpens in your device viewer
P RESS RELEASE
2011 third-quarter revenue
Villepinte, 26 October 2011
Consolidated Group revenue (IFRS)
| In thousands of euros | 2011 | 2010 | Change |
|---|---|---|---|
| First quarter +++++++++++++++ | 95,053 | 86,684 | +9.7% |
| Second quarter +++++++++++++ | 98,559 | 92,220 | +6.9% |
| Third quarter ++++++++++++++ | 87,138 | 82,797 | +5.2% |
| TotalJJJJJJJJJJJJJJJ | 280,750 | 261,701 | +7.3% |
Consolidated revenue by region
| In thousands of euros | 2011 | 2010 | Change |
|---|---|---|---|
| European subsidiaries+++++++++++ | 198,215 | 190,610 | +4.0% |
| Other markets++++++++++++++ | 82,535 | 71,090 | +16.1% |
| TotalJJJJJJJJJJJJJJJ | 280,750 | 261,701 | +7.3% |
2011 third-quarter sales highlights and full-year outlook
In the third quarter, Dotarem registered continued growth (+12.6% in value) with consistent performances across Europe and further gains in other markets. Over the same period, Xenetix experienced an acceleration with sales growth of 7.7%, particularly from momentum outside of Europe (+12.6%).
Year-to-date for the nine-month period ended 30 September, sales grew 7.3% driven by Dotarem (+15.3%), Lipiodol (+55.0%) and Xenetix (+3.7%). Asia, Latin America and North America accounted for 60% of total growth.
Since the beginning of the year, no production incidents were experienced adversely affecting activity. For year end, the trend of the first nine months is expected to be confirmed.
Contact: Administrative and Finance Department - Tel.: 01 45 91 50 69